68 Ga-P16-093
Networked: 1
relevant articles (0 outcomes,
0 trials/studies)
Bio-Agent Context: Research Results
Related Diseases
| 1. | Prostatic Neoplasms (Prostate Cancer)
|
| 2. | Neoplasms (Cancer)
04/01/2023
- " 68 Ga-P16-093 PET/CT exhibited higher tumor uptake and potentially better tumor detection capability than 68 Ga-PSMA-617 PET/CT, which suggested that 68 Ga-P16-093 may be more suitable in the diagnosis and staging of primary PCa patients." 04/01/2023
- " Further, 68 Ga-P16-093 PET/CT exhibited significantly higher SUV max of matched tumors (18.3 ± 14.4 vs 13.9 ± 11.8, P < 0.001). " 04/01/2023
- " 68 Ga-P16-093 PET/CT detected more positive tumors than 68 Ga-PSMA-617 PET/CT (67 vs 56, P = 0.002), especially for intraprostatic lesions (29 vs 24, P = 0.025) and lymph node metastases (23 vs 17, P = 0.034). " 04/01/2023
- " The SUV max of tumor measured by 68 Ga-P16-093 PET/CT had a moderate association with biopsy Gleason score ( r = 0.462, P = 0.005) and prostate-specific antigen value ( r = 0.491, P = 0.002), and significantly correlated with PSMA expression ( r = 0.732, P < 0.001). "
|
| 3. | Lymphatic Metastasis
|
|
Related Drugs and Biologics